Mendus

Mendus is a clinical-stage immunoncology (IO) company based in Sweden and the Netherlands. The company specialises in allogeneic dendritic cell biology and currently has two lead, cell-based, off-the-shelf therapies for haematological and solid tumours.

Equities

Equities by Sector

Sectors

Thematics

Latest

UK equities: A generational opportunity?

Renewable energy developers – Creating value for investors

Healthcare-focused trusts: A sector on the mend

Audiovisual

Latest

Oryzon Genomics – executive interview

Basilea Pharmaceutica – executive interview

Webinar – AI for IR: About our coaching programme

About Edison

About Edison

Careers

Mendus (OMX: IMMU)

Latest Insights

Mendus — Broad progress across the pipeline

Mendus – executive interview

Mendus — Collaboration unveils path forward for ilixadencel

Mendus — Recent clinical data highlight vididencel’s potential

Sector

Equity Analyst

Key Management

Mendus — Pursuit of a durable response in AML

Mendus — Phase II combination to progress lead asset

Mendus – executive interview

Mendus — Guarding against relapse

Mendus — ADVANCE II at ASH may be a near-term catalyst

Mendus — Vididencel secures Fast Track designation in AML

Mendus — Equipped for near-term inflection points

Mendus — Successful SEK317m equity raise

Mendus — Management update on vididencel in AML

Mendus — Financing to provide runway past catalysts

Mendus — Sights on vididencel (in AML) combination study

Mendus — Planning the route forward for vididencel in AML

Mendus — Momentum gathering across the pipeline

Mendus — Multi-front progression during FY22

Mendus — Improving survival beyond standard of care

Mendus — Positive phase II results for DCP-001 in AML

Mendus — No surprises in Q3 as DCP-001 readout nears

Mendus — Funding to see through key inflection points

Mendus — Next steps in anticipation of positive data

Mendus — Final EU grant payment of €1.69m expected

Mendus — Funding secured; catalyst rich H222 incoming

Mendus — DCP-001 in focus

Immunicum — Ilixandencel awarded orphan drug designation

Immunicum – executive interview

Immunicum — Positive interim data for DCP-001

Immunicum — Catalysts approaching for DCP-001

Immunicum — Primed for value appreciation

Immunicum — Potentially transformational merger

Immunicum — New CEO and data update from MERECA

Immunicum — FDA grants RMAT designation

Immunicum — Updated Phase II MERECA data positive

Immunicum — Full analysis of MERECA top-line results

Immunicum — Successful large share issue transforms outlook

Immunicum — Collaboration and supply agreement signed

Immunicum — Aiming to be ready to use in solid tumour combos

Immunicum — Very busy second half

Immunicum — Kicking the hornet’s nest of immunoncology